Search

Your search keyword '"Brunner, Hermine"' showing total 1,186 results
Start Over Author "Brunner, Hermine"
1,186 results on '"Brunner, Hermine"'

2. Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis

Author

Brunner, Hermine I, Schulert, Grant S, Sproles, Alyssa, Thornton, Sherry, Cornejo, Gabriel Vega, Antón, Jordi, Cuttica, Ruben, Henrickson, Michael, Foeldvari, Ivan, Kingsbury, Daniel J, Askelson, Margarita, Liu, Jinqi, Mukherjee, Sumanta, Wong, Robert L, Lovell, Daniel J, Martini, Alberto, Ruperto, Nicolino, and Grom, Alexei A

Published
2024
Full Text
View/download PDF

3. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis

Author

Brunner, Hermine I, Schulert, Grant S, Sproles, Alyssa, Thornton, Sherry, Cornejo, Gabriel Vega, Antón, Jordi, Cuttica, Ruben, Henrickson, Michael, Foeldvari, Ivan, Kingsbury, Daniel J, Askelson, Margarita, Liu, Jinqi, Mukherjee, Sumanta, Wong, Robert L, Lovell, Daniel J, Martini, Alberto, Ruperto, Nicolino, and Grom, Alexei A

Published
2024
Full Text
View/download PDF

6. Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce

Author

Connelly, Kathryn, Eades, Laura E., Koelmeyer, Rachel, Ayton, Darshini, Golder, Vera, Kandane-Rathnayake, Rangi, Gregory, Kate, Brunner, Hermine, Burke, Laurie, Arnaud, Laurent, Askanase, Anca, Aranow, Cynthia, Vital, Ed, Pons-Estel, Guillermo, Dantata, Khadija, Andersen, Jeanette, Cornet, Alain, Buie, Joy, Sun, Ying, Tanaka, Yoshiya, Simon, Lee, Lahoud, Youmna, Friedman, Alan, Kalunian, Kenneth, Zuraw, Qing, Werth, Victoria, Garces, Sandra, and Morand, Eric F.

Published
2023
Full Text
View/download PDF

8. Systemic Lupus Erythematosus

Author

Petri, Michelle, Aringer, Martin, Ayoub, Isabelle, Almaani, Salem, Brunner, Hermine, Dall’Era, Maria, Jiang, Mengdi, Furie, Richard, Greco, Jessica, Goldblatt, Fiona, Huggins, Jennifer, Huizinga, T. W. J., Isenberg, David, Li, Nicholas L., Monahan, R. C., Parikh, Samir V., Pisetsky, David, Puravath, Abin P., Rovin, Brad, Wallace, Daniel, Zhang, Xuan, Zhao, Lidan, and Stone, John H., editor

Published
2023
Full Text
View/download PDF

9. Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance

Author

Stotter, Brian R., Cody, Ellen, Gu, Hongjie, Daga, Ankana, Greenbaum, Larry A., Duong, Minh Dien, Mazo, Alexandra, Goilav, Beatrice, Boneparth, Alexis, Kallash, Mahmoud, Zeid, Ahmed, Seeherunvong, Wacharee, Scobell, Rebecca R., Alhamoud, Issa, Carter, Caitlin E., Shah, Siddharth, Straatmann, Caroline E., Dixon, Bradley P., Cooper, Jennifer C., Nelson, Raoul D., Levy, Deborah M., Brunner, Hermine I., Verghese, Priya S., and Wenderfer, Scott E.

Published
2023
Full Text
View/download PDF

11. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

Author

Viola, Diego, Spindler, Alberto, Akikusa, Jonathan, Chaitow, Jeffrey, Huemer, Christian, Dehoorne, Joke, Wouters, Carine, Lauwerys, Bernard, Boulanger, Cecile, Saad Magalhães, Claudia, Terreri, Maria, Li, Caifeng, Tang, Xuemei, Feng, Qihua, Yu, Haiguo, Zhou, Zhixuan, Dolezalova, Pavla, Horvath, Rudolf, Herlin, Troels, Glerup, Mia, Quartier Dit Maire, Pierre, Kone Paut, Isabelle, Gervais, Elisabeth, Belot, Alexandre, Name, Investigator, Horneff, Gerd, Minden, Kirsten, Trauzeddel, Ralf, Foeldvari, Ivan, Lutz, Thomas, Helling-Bakki, Astrid, Grulich-Henn, Jürgen, Kümmerle-Deschner, Jasmin, Sawhney, Sujata, Kumar, Sathish, Janarthanan, Mahesh, Amarilyo, Gil, Butbul, Yonatan, Uziel, Yosef, Tirosh, Irit, Harel, Liora, Caorsi, Roberta, Pastore, Serena, Tommasini, Alberto, Alessio, Maria, Breda, Luciana, Cattalini, Marco, Cimaz, Rolando, Giani, Teresa, Simonini, Gabriele, Filocamo, Giovanni, Umebayashi, Hiroaki, Kaneko, Utako, Kawano, Yutaka, Sato, Satoshi, Mori, Masaaki, Shimizu, Masaki, Yamaguchi, Kenichi, Ito, Shuichi, Imagawa, Tomoyuki, Inoue, Natsumi, Yokoyama, Tadafumi, Shabana, Kosuke, Ozeki, Yuka, Kawano, Yoshifumi, Yamasaki, Yuichi, Miyamae, Takako, Vega Cornejo, Gabriel, Rubio Perez, Nadina, Vargas, Edgar, Pacheco-Tena, Cesar, Edmundo Enriquez Sosa, Favio, Smolewska, Elzbieta, Zuber, Zbigniew, Gietka, Piotr, Alexeeva, Ekaterina, Nikishina, Irina, Valieva, Sania, Antón López, Jordi, Murias Loza, Sara, Maria Alcobendas Rueda, Rosa, Calvo Penades, Inmaculada, Grana, Genaro, Lucica Boteanu, Alina, Kasapcopur, Ozgur, Unsal, Erbil, Vaidyanathan Ramanan, Athimalaipet, Lacassagne, Sandrine, Hawley, Daniel, Mahmood, Kamran, Almeida, Beverley, Ramanan, Athimalaipet V, Quartier, Pierre, Okamoto, Nami, Fingerhutová, Šárka, Antón, Jordi, Wang, Zhongkai, Meszaros, Gabriella, Araújo, Joana, Liao, Ran, Keller, Stuart, Brunner, Hermine I, and Ruperto, Nicolino

Published
2023
Full Text
View/download PDF

12. Long‐Term Maintenance of Clinical Responses by Individual Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Abatacept

Author

Brunner, Hermine I., Tzaribachev, Nikolay, Louw, Ingrid, Calvo Penades, Inmaculada, Avila‐Zapata, Francisco, Horneff, Gerd, Foeldvari, Ivan, Kingsbury, Daniel J., Paz Gastanaga, Maria Eliana, Wouters, Carine, Breedt, Johannes, Wong, Robert, Askelson, Margarita, Zhuo, Joe, Martini, Alberto, Lovell, Daniel J., and Ruperto, Nicolino

Published
2023
Full Text
View/download PDF

15. Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis.

Author

Ogbu, Ekemini A., Brunner, Hermine I., Eloseily, Esraa, Aviel, Yonatan Butbul, Nanda, Kabita, Schmeling, Heinrike, Tory, Heather, Uziel, Yosef, Viola, Diego Oscar, Wahezi, Dawn M., Tarvin, Stacey E., Sproles, Alyssa, Chen, Chen, Ruperto, Nicolino, Huang, Bin, Grom, Alexei, and Thornton, Sherry

Subjects
CD54 antigen, TUMOR necrosis factor receptors, JUVENILE idiopathic arthritis, VASCULAR endothelial growth factors, TISSUE inhibitors of metalloproteinases, LEPTIN, VASCULAR cell adhesion molecule-1
Abstract

Objective: We examine levels of candidate blood‐based biomarkers (CBBs) in patients with juvenile idiopathic arthritis (JIA) treated with tofacitinib. Methods: Patients with JIA who participated in clinical trial NCT02592434 received tofacitinib from baseline to week 18. Serial serum samples were assayed for CBBs (S100A8/9, S100A12, interleukin‐18 [IL‐18], serum amyloid A, resistin, vascular endothelial growth factor, angiopoietin‐1, angiopoietin‐2, matrix metalloproteinase 8 [MMP8], MMP2, tissue inhibitor of metalloproteinases 1, leptin, chemokine [C‐X‐C motif] ligand 9, soluble IL‐2 receptor, intercellular adhesion molecule 1, soluble tumor necrosis factor receptor, IL‐6, IL‐23, monocyte chemotactic protein 1, chemokine [C‐C motif] ligand 18 [CCL18], and CCL20). Association of CBBs with JIA response to treatment from baseline to week 18 were assessed. Results: This study included 166 patients with polyarticular‐course JIA. Paired serum samples from 143 patients were available at both baseline and week 18. Thirty‐five percent (50 of 143) of patients had a JIA‐American College of Rheumatology 90 (JIA‐ACR90) level improvement, whereas 90, 121, and 137 (63%, 85%, and 96%) achieved JIA‐ACR70, 50, and 30 improvement at week 18. Despite small numerical differences by JIA category, there were no baseline CBB values that independently predicted a decrease in Juvenile Arthritis Disease Activity Score (JADAS‐27) or JIA‐ACR90 response by week 18. Decrease in resistin level (baseline to week 18) was significantly associated with week 18 improvement in JADAS‐27 and JIA‐ACR90 response after adjusting for age, sex, JIA disease duration, and baseline resistin (r2 0.79, SE 0.070, P < 0.01, and odds ratio [95% confidence interval] 1.134 [1.018–1.264]). HLA‐B27 positivity was significantly associated with not achieving a JIA‐ACR90 response at week 18 (P = 0.0097). Conclusion: Among the CBBs included, only resistin was significantly associated with treatment response, and no CBB was identified that forecasts JIA improvement after initiation of tofacitinib. The association of HLA‐B27 positivity with lower response to tofacitinib in JIA is intriguing and merits further study. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study.

Author

Brunner, Hermine I., Pacheco-Tena, César, Louw, Ingrid, Vega-Cornejo, Gabriel, Alexeeva, Ekaterina, Appenzeller, Simone, Chasnyk, Vyacheslav, Griffin, Thomas, Navarrete Suarez, Carmen, Knupp-Oliveira, Sheila, Zeft, Andrew, Aviel, Yonatan Butbul, De Ranieri, Deirdre, Gottlieb, Beth S., Levy, Deborah M., Rabinovich, C. Egla, Silva, Clóvis Artur, Spivakovsky, Yury, Uziel, Yosef, and Ringold, Sarah

Published
2024
Full Text
View/download PDF

18. Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.

Author

Brunner, Hermine I., Akikusa, Jonathan D., Al-Abadi, Eslam, Bohnsack, John F., Boteanu, Alina Lucica, Chedeville, Gaelle, Cuttica, Ruben, De La Pena, Wendy, Jung, Lawrence, Kasapcopur, Ozgur, Kobusinska, Katarzyna, Schulert, Grant S., Neiva, Claudia, Rivas-Chacon, Rafael, Rizo Rodriguez, Juan Cruz, Vazquez-Del Mercado, Monica, Wagner-Weiner, Linda, Weiss, Jennifer E., Wouters, Carine, and Posner, Holly

Published
2024
Full Text
View/download PDF

21. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Author

Johnson, Sindhu R., Gladman, Dafna D., Brunner, Hermine I., Isenberg, David, Clarke, Ann E., Barber, Megan R. W., Arnaud, Laurent, Fortin, Paul R., Mosca, Marta, Voskuyl, Alexandre E., Manzi, Susan, Aranow, Cynthia, Askanase, Anca, Alarcón, Graciela S., Bae, Sang‐Cheol, Costedoat‐Chalumeau, Nathalie, English, Jessica A., Pons‐Estel, Guillermo J., Pons‐Estel, Bernardo A., Gilman, Rebecca, Ginzler, Ellen M., Hanly, John G., Jacobsen, Soren, Kalunian, Kenneth, Kamen, Diane L., Lambalgen, Chynace, Legge, Alexandra, Lim, S. Sam, Mak, Anselm, Morand, Eric F., Peschken, Christine A., Petri, Michelle, Rahman, Anisur, Ramsey‐Goldman, Rosalind, Reynolds, John A., Romero‐Diaz, Juanita, Ruiz‐Irastorza, Guillermo, Sanchez‐Guerrero, Jorge, Svenungsson, Elisabet, Touma, Zahi, Urowitz, Murray, Vinet, Evelyne, van Vollenhoven, Ronald F., Waldhauser, Heather, Wallace, Daniel J., Zoma, Asad, and Bruce, Ian N.

Published
2023
Full Text
View/download PDF

22. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis

Author

Cooper, Jennifer C, Rouster-Stevens, Kelly, Wright, Tracey B, Hsu, Joyce J, Klein-Gitelman, Marisa S, Ardoin, Stacy P, Schanberg, Laura E, Brunner, Hermine I, Eberhard, B Anne, Wagner-Weiner, Linda, Mehta, Jay, Haines, Kathleen, McCurdy, Deborah K, Phillips, Thomas A, Huang, Zhen, and von Scheven, Emily

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Autoimmune Disease, Pediatric, Kidney Disease, Comparative Effectiveness Research, Arthritis, Clinical Research, Health Services, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Inflammatory and immune system, Adolescent, Child, Cohort Studies, Consensus, Cyclophosphamide, Feasibility Studies, Female, Glucocorticoids, Guideline Adherence, Humans, Immunosuppressive Agents, Kidney, Lupus Nephritis, Male, Mycophenolic Acid, Pilot Projects, Prospective Studies, Registries, Remission Induction, Rheumatology, Treatment Outcome, Juvenile systemic lupus erythematosus, Lupus nephritis, Mycophenolate, Corticosteroids, CARRA registry investigators, Paediatrics and Reproductive Medicine, Arthritis & Rheumatology, Clinical sciences, Paediatrics
Abstract

BackgroundTo reduce treatment variability and facilitate comparative effectiveness studies, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) published consensus treatment plans (CTPs) including one for juvenile proliferative lupus nephritis (LN). Induction immunosuppression CTPs outline treatment with either monthly intravenous (IV) cyclophosphamide (CYC) or mycophenolate mofetil (MMF) in conjunction with one of three corticosteroid (steroid) CTPs: primarily oral, primarily IV or mixed oral/IV. The acceptability and in-practice use of these CTPs are unknown. Therefore, the primary aims of the pilot study were to demonstrate feasibility of adhering to the LN CTPs and delineate barriers to implementation in clinical care in the US. Further, we aimed to explore the safety and effectiveness of the treatments for induction therapy.MethodsForty-one patients were enrolled from 10 CARRA sites. Patients had new-onset biopsy proven ISN/RPS class III or IV proliferative LN, were starting induction therapy with MMF or IV CYC and high-dose steroids and were followed for up to 24 months. Routine clinical data were collected at each visit. Provider reasons for CTP selection were assessed at baseline. Adherence to the CTPs was evaluated by provider survey and medication logs. Complete and partial renal responses were reported at 6 months.ResultsThe majority of patients were female (83%) with a mean age of 14.7 years, SD 2.8. CYC was used more commonly than MMF for patients with ISN/RPS class IV LN (vs. class III), those who had hematuria, and those with adherence concerns. Overall adherence to the immunosuppression induction CTPs was acceptable with a majority of patients receiving the target MMF (86%) or CYC (63%) dose. However, adherence to the steroid CTPs was poor (37%) with large variability in dosing. Renal response endpoints were exploratory and did not show a significant difference between CYC and MMF.ConclusionsOverall, the immunosuppression CTPs were followed as intended in the majority of patients however, adherence to the steroid CTPs was poor indicating revision is necessary. In addition, our pilot study revealed several sources of treatment selection bias that will need to be addressed in for future comparative effectiveness research.

Published
2018

24. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

Author

Cuttica, R, Akikusa, J, Chaitow, J, Wouters, C, Oliveira, S, Neiva, CLS, Santiago, M, Silva, CA, Terreri, MT, Magalhaes, C, De Souza, V, Bandeira, M, Chédeville, G, Houghton, K, Vazquez-Del Mercado, M, Rizo Rodriguez, J, Kobusinska, K, Alexeeva, E, Calvo Penades, I, Boteanu, AL, Kasapcopur, O, Poyrazoglu, MH, Erguven, M, Ozen, S, Al-Abadi, E, Bohnsack, J, Carrasco, R, Dare, J, Gottlieb, B, Wahezi, D, Jung, L, Klein-Gitelman, M, Zhang, Y, Wagner-Weiner, L, Tarvin, S, Vehe, RK, Chiraseveenuprapund, P, Rivas-Chacon, R, De La Pena, W, Sagcal-Gironella, ACP, Weiss, JE, Ruperto, Nicolino, Brunner, Hermine I, Synoverska, Olga, Ting, Tracy V, Mendoza, Carlos Abud, Spindler, Alberto, Vyzhga, Yulia, Marzan, Katherine, Grebenkina, Lyudmila, Tirosh, Irit, Imundo, Lisa, Jerath, Rita, Kingsbury, Daniel J, Sozeri, Betul, Vora, Sheetal S, Prahalad, Sampath, Zholobova, Elena, Butbul Aviel, Yonatan, Chasnyk, Vyacheslav, Lerman, Melissa, Nanda, Kabita, Schmeling, Heinrike, Tory, Heather, Uziel, Yosef, Viola, Diego O, Posner, Holly B, Kanik, Keith S, Wouters, Ann, Chang, Cheng, Zhang, Richard, Lazariciu, Irina, Hsu, Ming-Ann, Suehiro, Ricardo M, Martini, Alberto, and Lovell, Daniel J

Published
2021
Full Text
View/download PDF

26. Transancestral mapping and genetic load in systemic lupus erythematosus.

Author

Langefeld, Carl D, Ainsworth, Hannah C, Cunninghame Graham, Deborah S, Kelly, Jennifer A, Comeau, Mary E, Marion, Miranda C, Howard, Timothy D, Ramos, Paula S, Croker, Jennifer A, Morris, David L, Sandling, Johanna K, Almlöf, Jonas Carlsson, Acevedo-Vásquez, Eduardo M, Alarcón, Graciela S, Babini, Alejandra M, Baca, Vicente, Bengtsson, Anders A, Berbotto, Guillermo A, Bijl, Marc, Brown, Elizabeth E, Brunner, Hermine I, Cardiel, Mario H, Catoggio, Luis, Cervera, Ricard, Cucho-Venegas, Jorge M, Dahlqvist, Solbritt Rantapää, D'Alfonso, Sandra, Da Silva, Berta Martins, de la Rúa Figueroa, Iñigo, Doria, Andrea, Edberg, Jeffrey C, Endreffy, Emőke, Esquivel-Valerio, Jorge A, Fortin, Paul R, Freedman, Barry I, Frostegård, Johan, García, Mercedes A, de la Torre, Ignacio García, Gilkeson, Gary S, Gladman, Dafna D, Gunnarsson, Iva, Guthridge, Joel M, Huggins, Jennifer L, James, Judith A, Kallenberg, Cees GM, Kamen, Diane L, Karp, David R, Kaufman, Kenneth M, Kottyan, Leah C, Kovács, László, Laustrup, Helle, Lauwerys, Bernard R, Li, Quan-Zhen, Maradiaga-Ceceña, Marco A, Martín, Javier, McCune, Joseph M, McWilliams, David R, Merrill, Joan T, Miranda, Pedro, Moctezuma, José F, Nath, Swapan K, Niewold, Timothy B, Orozco, Lorena, Ortego-Centeno, Norberto, Petri, Michelle, Pineau, Christian A, Pons-Estel, Bernardo A, Pope, Janet, Raj, Prithvi, Ramsey-Goldman, Rosalind, Reveille, John D, Russell, Laurie P, Sabio, José M, Aguilar-Salinas, Carlos A, Scherbarth, Hugo R, Scorza, Raffaella, Seldin, Michael F, Sjöwall, Christopher, Svenungsson, Elisabet, Thompson, Susan D, Toloza, Sergio MA, Truedsson, Lennart, Tusié-Luna, Teresa, Vasconcelos, Carlos, Vilá, Luis M, Wallace, Daniel J, Weisman, Michael H, Wither, Joan E, Bhangale, Tushar, Oksenberg, Jorge R, Rioux, John D, Gregersen, Peter K, Syvänen, Ann-Christine, Rönnblom, Lars, Criswell, Lindsey A, Jacob, Chaim O, Sivils, Kathy L, Tsao, Betty P, Schanberg, Laura E, and Behrens, Timothy W

Subjects
Humans, Lupus Erythematosus, Systemic, HLA Antigens, Logistic Models, Case-Control Studies, Mutagenesis, Insertional, Age of Onset, Sequence Deletion, Genetic Load, Multifactorial Inheritance, Polymorphism, Single Nucleotide, African Continental Ancestry Group, American Native Continental Ancestry Group, European Continental Ancestry Group, Hispanic Americans, Lupus Erythematosus, Systemic, Mutagenesis, Insertional, Polymorphism, Single Nucleotide
Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease with marked gender and ethnic disparities. We report a large transancestral association study of SLE using Immunochip genotype data from 27,574 individuals of European (EA), African (AA) and Hispanic Amerindian (HA) ancestry. We identify 58 distinct non-HLA regions in EA, 9 in AA and 16 in HA (∼50% of these regions have multiple independent associations); these include 24 novel SLE regions (P

Published
2017

29. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.

Author

Brunner, Hermine I, Ruperto, Nicolino, Ramanan, Athimalaipet V, Horneff, Gerd, Minden, Kirsten, Penades, Inmaculada Calvo, Alexeeva, Ekaterina, Cleary, Gavin, Stern, Sara M, Kone-Paut, Isabelle, Velázquez, María del Rocío Maldonado, Rabinovich, C Egla, Remesal, Agustin, Silva, Clovis Artur, Nikishina, Irina, Zucchetto, Mauro, Brockwell, Laura, Gordon, Oliver, Nagel, Sandra, and Benedetti, Fabrizio De

Subjects
*THERAPEUTIC use of monoclonal antibodies, *JUVENILE idiopathic arthritis, *PATIENT safety, *RESEARCH funding, *CLINICAL trials, *DESCRIPTIVE statistics, *MONOCLONAL antibodies, *DRUG efficacy, *TOCILIZUMAB, *SUBCUTANEOUS injections, *INTERLEUKINS, *EVALUATION, *CHILDREN
Abstract

Objective To investigate the safety and efficacy of subcutaneous tocilizumab (SC-TCZ) treatment in a long-term extension (LTE) of clinical trials in polyarticular or systemic juvenile idiopathic arthritis (pJIA or sJIA). Methods Patients with pJIA or sJIA from two open-label, 52-week phase 1b core trials of SC-TCZ who had adequate response per investigator assessment entered the LTE and continued SC-TCZ treatment according to body weight–based dosing regimens until commercial availability or up to 5 years. Pharmacokinetics, pharmacodynamics, and efficacy were assessed for up to 3 years, and safety for up to 5 years in the LTE. Results Forty-four patients with pJIA and 38 patients with sJIA entered the LTE. Tocilizumab trough concentrations were maintained within the range expected to provide clinical benefit (mean values: pJIA, ∼10 μg/ml; sJIA, ∼75 μg/ml over 3 years). Pharmacodynamic parameters (interleukin-6, soluble interleukin-6 receptor, erythrocyte sedimentation rate, C-reactive protein) were maintained throughout the LTE at levels achieved in the core trials. Inactive disease per American College of Rheumatology provisional criteria was reported for 90% (17/19) and 53% (8/15) of patients with pJIA and 91% (10/11) and 92% (12/13) of patients with sJIA in the <30 and ≥30 kg body weight groups, respectively. Serious adverse events in the LTE were reported in six patients with pJIA (13.6%; five serious infections) and five patients with sJIA (13.2%; one serious infection). Conclusion Patients with pJIA or sJIA experienced long-term disease control with SC-TCZ treatment. Long-term safety was consistent with the known tocilizumab safety profile. Clinical trial registration clinicaltrials.gov, NCT02165345 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Revisiting Childhood-Onset Systemic Lupus Erythematosus.

Author

Avar-Aydın, Pınar Özge and Brunner, Hermine I.

Subjects
*NEPHRITIS, *HEART diseases, *IMMUNOSUPPRESSIVE agents, *DISEASE management, *AUTOANTIBODIES, *CUTANEOUS manifestations of general diseases, *MUCOUS membranes, *MUSCULOSKELETAL system diseases, *SYSTEMIC lupus erythematosus, *TREATMENT effectiveness, *AGE factors in disease, *DISEASES, *PATIENT-centered care, *CLINICAL pathology, *QUALITY of life, *NEUROPSYCHOLOGY, *LUNG diseases, *INDIVIDUALIZED medicine, *BLOOD diseases, *KIDNEY diseases, *HEALTH care teams, *GASTROINTESTINAL diseases, *DISEASE complications, *SYMPTOMS, *CHILDREN
Abstract

Childhood-onset systemic lupus erythematosus (cSLE) is a chronic autoimmune disease with a multisystemic involvement diagnosed during childhood. The disease is marked by the production of autoantibodies targeting self-antigens, often before symptoms emerge. The presentation, clinical course, and outcome vary significantly among patients with cSLE. The onset of cSLE can be at any age during childhood while a diagnosis of cSLE before the age of 5 years is rare and raises a suspicion of monogenic lupus. Childhood-onset systemic lupus erythematosus affects various organs and systems, most frequently presenting with mucocutaneous, musculoskeletal, renal, and neuropsychiatric manifestations. Multiple disease flares can be seen during the disease course. Childhood-onset systemic lupus erythematosus causes significant morbidity and mortality. Children and adolescents with cSLE show higher disease activity and damage, and more aggressive immunosuppressive treatments are needed compared to adultonset SLE. Early diagnosis can be difficult due to the insidious onset with nonspecific symptoms. Disease activity and damage measures aim to ensure an accurate evaluation of disease status. A multidisciplinary approach and individualized disease management are important. Disease management is complex including the control of disease activity, the reduction of flares and damage, and a limitation of drug toxicity while improving the health-related quality of life in patients with cSLE. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry

Author

Lovell, Daniel J, primary, Tzaribachev, Nikolay, additional, Henrickson, Michael, additional, Simonini, Gabriele, additional, Griffin, Thomas A, additional, Alexeeva, Ekaterina, additional, Bohnsack, John F, additional, Zeft, Andrew, additional, Horneff, Gerd, additional, Vehe, Richard K, additional, Staņēviča, Valda, additional, Tarvin, Stacey, additional, Trachana, Maria, additional, del Río, Ana Quintero, additional, Huber, Adam M, additional, Kietz, Daniel, additional, Orbán, Ilonka, additional, Dare, Jason, additional, Foeldvari, Ivan, additional, Quartier, Pierre, additional, Dominique, Alyssa, additional, Simon, Teresa A, additional, Martini, Alberto, additional, Brunner, Hermine I, additional, and Ruperto, Nicolino, additional

Published
2024
Full Text
View/download PDF

36. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein

Author

Ardoin, Stacy P, Schanberg, Laura Eve, Sandborg, Christy I, Barnhart, Huiman X, Evans, Greg W, Yow, Eric, Mieszkalski, Kelly L, Ilowite, Norman T, Eberhard, Anne, Imundo, Lisa F, Kimura, Yuki, Levy, Deborah, von Scheven, Emily, Silverman, Earl, Bowyer, Suzanne L, Punaro, L, Singer, Nora G, Sherry, David D, McCurdy, Deborah K, Klein-Gitelman, Marissa, Wallace, Carol, Silver, Richard M, Wagner-Weiner, Linda, Higgins, Gloria C, Brunner, Hermine I, Jung, Lawrence, Soep, Jennifer B, Reed, Ann M, Thompson, Susan D, and investigators, for the APPLE

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Autoimmune Disease, Clinical Research, Atherosclerosis, Clinical Trials and Supportive Activities, Lupus, Cardiovascular, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Age Factors, Atorvastatin, Biomarkers, C-Reactive Protein, Carotid Arteries, Carotid Intima-Media Thickness, Cholesterol, LDL, Disease Progression, Double-Blind Method, Female, Heptanoic Acids, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lupus Erythematosus, Systemic, Male, Prospective Studies, Puberty, Pyrroles, Treatment Outcome, Systemic Lupus Erythematosus, Autoimmune Diseases, APPLE investigators, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveParticipants in the Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) trial were randomised to placebo or atorvastatin for 36 months. The primary endpoint, reduced carotid intima medial thickness (CIMT) progression, was not met but atorvastatin-treated participants showed a trend of slower CIMT progression. Post-hoc analyses were performed to assess subgroup benefit from atorvastatin therapy.MethodsSubgroups were prespecified and defined by age (> or ≤15.5 years), systemic lupus erythematosus (SLE) duration (> or ≤24 months), pubertal status (Tanner score≥4 as post-pubertal or

Published
2014

40. Biological Variability of Estimated GFR and Albuminuria in CKD

Author

Ramachandran, Vasan S., Bonventre, Joseph, Waikar, Sushrut, Sabbisetti, Venkata, Van Eyk, Jennifer, Chen, Dawn, Fu, Qin, Brunner, Hermine, D’Agati, Vivette, Barasch, Jonathan, Coresh, Josef, Rebholz, Casey, Go, Alan S., Bottinger, Erwin, Teixeira, Avelino, Daehn, Ilse, Molitch, Mark, Batlle, Daniel, Rovin, Brad, Wu, Haifeng, Levey, Andrew S., Inker, Lesley A., Foster, Meredith, Hsu, Chi-yuan, Liu, Kathleen, Klein, Jon, Mauer, Michael, Fioretto, Paola, Nelsestuen, Gary, Eckfeldt, John H., Karger, Amy, Feldman, Harold I., Ballard, Shawn, Whitehead, Krista, Xie, Dawei, Gimotty, Phyllis, Shou, Haochang, Zhang, Xiaoming, Ryan, Kellie, Mifflin, Theodore E., Greene, Tom, Nelson, Robert G., Kimmel, Paul L., Kusek, John W., Waikar, Sushrut S., Rebholz, Casey M., Zheng, Zihe, Hurwitz, Shelley, Liu, Kathleen D., Vasan, Ramachandran S., and Bonventre, Joseph V.

Published
2018
Full Text
View/download PDF

43. Cancer risk in childhood-onset systemic lupus

Author

Bernatsky, Sasha, Clarke, Ann E, Labrecque, Jeremy, von Scheven, Emily, Schanberg, Laura E, Silverman, Earl D, Brunner, Hermine I, Haines, Kathleen A, Cron, Randy Q, O’Neil, Kathleen M, Oen, Kiem, Rosenberg, Alan M, Duffy, Ciarán M, Joseph, Lawrence, Lee, Jennifer L, Kale, Mruganka, Turnbull, Elizabeth M, and Ramsey-Goldman, Rosalind

Abstract

Abstract Introduction The aim of this study was to assess cancer incidence in childhood-onset systemic lupus erythematosus (SLE). Methods We ascertained cancers within SLE registries at 10 pediatric centers. Subjects were linked to cancer registries for the observational interval, spanning 1974 to 2009. The ratio of observed to expected cancers represents the standardized incidence ratio (SIR) or relative cancer risk in childhood-onset SLE, versus the general population. Results There were 1020 patients aged

Published
2013

44. Cancer risk in childhood-onset systemic lupus.

Author

Schanberg, Laura, Silverman, Earl, Brunner, Hermine, Haines, Kathleen, Cron, Randy, ONeil, Kathleen, Oen, Kiem, Rosenberg, Alan, Duffy, Ciarán, Joseph, Lawrence, Lee, Jennifer, Kale, Mruganka, Turnbull, Elizabeth, Ramsey-Goldman, Rosalind, Bernatsky, Sasha, Clarke, Ann, Labrecque, Jeremy, and Von Scheven, Emily

Subjects
Adolescent, Age of Onset, Child, Female, Humans, Incidence, Lupus Erythematosus, Systemic, Male, Neoplasms, Registries, Risk Factors
Abstract

INTRODUCTION: The aim of this study was to assess cancer incidence in childhood-onset systemic lupus erythematosus (SLE). METHODS: We ascertained cancers within SLE registries at 10 pediatric centers. Subjects were linked to cancer registries for the observational interval, spanning 1974 to 2009. The ratio of observed to expected cancers represents the standardized incidence ratio (SIR) or relative cancer risk in childhood-onset SLE, versus the general population. RESULTS: There were 1020 patients aged

Published
2013

46. The effects of early aggressive therapy in JIA: results of the TREAT study

Author

Wallace, Carol A, Giannini, Edward H, Spalding, Steven J, Hashkes, Philip J, O’Neil, Kathleen M, Zeft, Andrew S, Szer, Ilona S, Ringold, Sarah M, Brunner, Hermine, Schanberg, Laura E, Sundel, Robert P, Milojevic, Diana, Punaro, Marilynn G, Chira, Peter, Gottlieb, Beth S, Higgins, Gloria C, Ilowite, Norman T, Kimura, Yukiko, Huang, Bin, and Lovell, Daniel J

Published
2012

48. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

Author

Ramanan, Athimalaipet V, primary, Quartier, Pierre, additional, Okamoto, Nami, additional, Foeldvari, Ivan, additional, Spindler, Alberto, additional, Fingerhutová, Šárka, additional, Antón, Jordi, additional, Wang, Zhongkai, additional, Meszaros, Gabriella, additional, Araújo, Joana, additional, Liao, Ran, additional, Keller, Stuart, additional, Brunner, Hermine I, additional, Ruperto, Nicolino, additional, Viola, Diego, additional, Akikusa, Jonathan, additional, Chaitow, Jeffrey, additional, Huemer, Christian, additional, Dehoorne, Joke, additional, Wouters, Carine, additional, Lauwerys, Bernard, additional, Boulanger, Cecile, additional, Saad Magalhães, Claudia, additional, Terreri, Maria, additional, Li, Caifeng, additional, Tang, Xuemei, additional, Feng, Qihua, additional, Yu, Haiguo, additional, Zhou, Zhixuan, additional, Dolezalova, Pavla, additional, Horvath, Rudolf, additional, Herlin, Troels, additional, Glerup, Mia, additional, Quartier Dit Maire, Pierre, additional, Kone Paut, Isabelle, additional, Gervais, Elisabeth, additional, Belot, Alexandre, additional, Name, Investigator, additional, Horneff, Gerd, additional, Minden, Kirsten, additional, Trauzeddel, Ralf, additional, Lutz, Thomas, additional, Helling-Bakki, Astrid, additional, Grulich-Henn, Jürgen, additional, Kümmerle-Deschner, Jasmin, additional, Sawhney, Sujata, additional, Kumar, Sathish, additional, Janarthanan, Mahesh, additional, Amarilyo, Gil, additional, Butbul, Yonatan, additional, Uziel, Yosef, additional, Tirosh, Irit, additional, Harel, Liora, additional, Caorsi, Roberta, additional, Pastore, Serena, additional, Tommasini, Alberto, additional, Alessio, Maria, additional, Breda, Luciana, additional, Cattalini, Marco, additional, Cimaz, Rolando, additional, Giani, Teresa, additional, Simonini, Gabriele, additional, Filocamo, Giovanni, additional, Umebayashi, Hiroaki, additional, Kaneko, Utako, additional, Kawano, Yutaka, additional, Sato, Satoshi, additional, Mori, Masaaki, additional, Shimizu, Masaki, additional, Yamaguchi, Kenichi, additional, Ito, Shuichi, additional, Imagawa, Tomoyuki, additional, Inoue, Natsumi, additional, Yokoyama, Tadafumi, additional, Shabana, Kosuke, additional, Ozeki, Yuka, additional, Kawano, Yoshifumi, additional, Yamasaki, Yuichi, additional, Miyamae, Takako, additional, Vega Cornejo, Gabriel, additional, Rubio Perez, Nadina, additional, Vargas, Edgar, additional, Pacheco-Tena, Cesar, additional, Edmundo Enriquez Sosa, Favio, additional, Smolewska, Elzbieta, additional, Zuber, Zbigniew, additional, Gietka, Piotr, additional, Alexeeva, Ekaterina, additional, Nikishina, Irina, additional, Valieva, Sania, additional, Antón López, Jordi, additional, Murias Loza, Sara, additional, Maria Alcobendas Rueda, Rosa, additional, Calvo Penades, Inmaculada, additional, Grana, Genaro, additional, Lucica Boteanu, Alina, additional, Kasapcopur, Ozgur, additional, Unsal, Erbil, additional, Vaidyanathan Ramanan, Athimalaipet, additional, Lacassagne, Sandrine, additional, Hawley, Daniel, additional, Mahmood, Kamran, additional, and Almeida, Beverley, additional

Published
2023
Full Text
View/download PDF

49. Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials

Author

Ruperto, Nicolino, primary, Lovell, Daniel J., additional, Berman, Alberto, additional, Anton, Jordi, additional, Viola, Diego O., additional, Lauwerys, Bernard, additional, Rama, Maria E., additional, Bohnsack, John, additional, Breedt, Johannes, additional, Fischbach, Michel, additional, Lutz, Thomas, additional, Minden, Kirsten, additional, Ally, Mahmood, additional, Rubio-Pérez, Nadina, additional, Gervais, Elisabeth, additional, Van Zyl, Riana, additional, Wong, Robert, additional, Askelson, Margarita, additional, Martini, Alberto, additional, and Brunner, Hermine I., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results